Glaucoma News and Research

Latest Glaucoma News and Research

AHAF awards 22 new grants to scientists worldwide for innovative vision research

The American Health Assistance Foundation (AHAF), a nonprofit organization with a history of funding cutting-edge research on age-related diseases, announced today that it has awarded 22 new grants totaling nearly $2.2 million to scientists worldwide who are studying glaucoma and macular degeneration. The two conditions are the leading causes of irreversible vision loss and blindness in the U.S.

8 Jul 2011

Healthy diet might help reduce risk of macular degeneration

Eating a diet high in vitamin D, as well as the nutrients betaine and methionine, might help reduce the risk of macular degeneration, according to new research conducted by Tufts Medical Center scientists. Their study of identical twins from the US World War II Twin Registry also found that the more a person smoked, the higher their risk of developing macular degeneration.

6 Jul 2011

Anabasis, Scil Proteins enter license deal for rhNGF to treat eye diseases

Scil Proteins, a private biopharmaceutical company specialized in the research, development and production of recombinant proteins, today announced that it has signed an agreement with Anabasis Pharma.

30 Jun 2011

STSI joins JAX consortium to develop targeted cancer therapies

The Scripps Translational Science Institute (STSI) of San Diego, Calif., has joined a national consortium of research institutions headed by The Jackson Laboratory (JAX) that is building a library of primary human tumors with the goal of developing highly targeted cancer therapies.

30 Jun 2011

Positive top line data from Mimetogen MIM-D3 Phase II clinical trial for dry eye disease

Mimetogen Pharmaceuticals Inc. today announced positive top line data from the Phase II clinical trial of MIM-D3 for dry eye disease. The trial demonstrated statistically significant improvements in signs and symptoms with its low (1%) and high (5%) doses of MIM-D3, together with excellent safety and tolerability profiles.

27 Jun 2011

Ivantis receives $17 MM NEA, Delphi Ventures funds to expand Hydrus device clinical activities

Ivantis announced today at the World Glaucoma Congress in Paris that it has received $17 MM in funding from New Enterprise Associates (NEA) and Delphi Ventures.

27 Jun 2011

Anticholinergic drugs might increase risk of cognitive impairment, death in older people

A side effect of many commonly used drugs appears to increase the risks of both cognitive impairment and death in older people, according to new research led by the University of East Anglia.

24 Jun 2011

New VEP technique fast and effective for detecting glaucoma damage

A recent paper published in the Journal of Glaucoma shows a new visual evoked potential (VEP) technique to be a fast, objective method to screen for functional damage in glaucomatous eyes.

22 Jun 2011

Functional vision restored after 55 years

After being hit in the eye by a stone, a detached retina left a man blind in his right eye. Despite surgery to remove a cataract when the man was 23, which temporarily restored light perception, the patient was completely blind in that eye.

17 Jun 2011

InNexus files patent protection for new Age-related Macular Degeneration therapeutic

InNexus Biotechnology Inc., a biopharmaceutical company creating and developing innovative solutions for cancer, inflammation and other difficult-to-treat diseases, announced today that it has filed for patent protection covering a novel antibody product for Age-related Macular Degeneration (AMD) and other eye disorders.

16 Jun 2011

Pfizer, pSivida partner to develop latanoprost implant for ocular hypertension and glaucoma

Drug delivery company pSivida Corp today announced it amended and restated its Research and Development Agreement with Pfizer Inc. to focus solely on the development of a long-term, sustained-release implant to deliver latanoprost for patients with ocular hypertension and glaucoma.

15 Jun 2011

Cypress receives FDA approval for ZUTRIPRO, REZIRA NDA to treat cough and common cold

Cypress Pharmaceutical announced today that the Food and Drug Administration (FDA) approved a new drug application (NDA) for ZUTRIPRO Oral Solution (CIII) and REZIRA Oral Solution.

14 Jun 2011

Schepens, Mass. Eye and Ear to create world's largest ophthalmology research center

The Massachusetts Eye and Ear Infirmary and Schepens Eye Research Institute announced today that they are combining forces to create the world's largest and most robust basic and clinical ophthalmology research enterprise with full spectrum bench-to-bedside research that will translate more quickly into better treatment for blinding diseases and ultimately cures.

10 Jun 2011

Paladin to commercialize Silenor for treatment of insomnia in Canada, South America and Africa

Somaxon Pharmaceuticals, Inc. and Paladin Labs Inc. today announced that they have entered into an exclusive collaboration under which Paladin will commercialize Silenor® (doxepin) for the treatment of insomnia characterized by difficulty with sleep maintenance in Canada, South America and Africa.

8 Jun 2011

New Westchester Montefiore Laser and Eye Center to offer ophthalmology services

The new Montefiore Laser and Eye Center recently opened its doors to provide comprehensive care to Westchester patients at the Montefiore Medical Specialists of Westchester in Scarsdale, New York. Seven board-certified ophthalmologists from the Department of Ophthalmology and Visual Sciences at Montefiore Medical Center provide patients with specialty emphasis in pediatric ophthalmology, oculoplastic surgery, glaucoma, cornea and laser refractive surgery.

8 Jun 2011

Denali, Can-Fite sign agreement to conclude ophthalmology spinoff

Can-Fite BioPharma Ltd, a biotechnology company developing small molecule drugs for the treatment of inflammatory, ophthalmic, and liver diseases, traded on the Tel Aviv Stock Exchange, signed today an agreement to spin off its ophthalmic indications to a US based public company, Denali Concrete Management Inc.

6 Jun 2011

Research: Gene mutation causes eye disease glaucoma

It is a mutation in a gene that causes the eye disease glaucoma, according to collaborative research conducted by Swedish, Tunisian, and American researchers. The findings were recently published in the journal Nature Genetics.

31 May 2011

Wills Eye Institute and Thomas Jefferson University create new vision research center

A new vision research center based in Philadelphia will foster regional, national and global collaborations among a diverse group of exceptional clinicians and researchers working to better diagnose, treat and prevent visual diseases.

21 May 2011

The Incubation Factory, UMDNJ and NJIT partner to commercialize personal tonometer for glaucoma

NJIT and UMDNJ have executed a license agreement with The Incubation Factory, St. Louis, MO, covering their personal tonometer technology on which a patent is pending. The tonometer was developed by a research team led by NJIT Professor Gordon Thomas, PhD, and Robert Fechtner, MD, director of the glaucoma division at UMDNJ.

18 May 2011

Positive results from Astellas Pharma's mirabegron phase III trial in overactive bladder

Astellas Pharma US, Inc., U.S. subsidiary of Astellas Pharma Inc., today announced the results of a pivotal phase III clinical trial for mirabegron, the first of a new class of compounds under development for the treatment of overactive bladder (OAB), which show mirabegron significantly improves key OAB symptoms – urinary incontinence and frequency of micturition compared with placebo.

18 May 2011

Glaucoma News and Research

Latest Glaucoma News and Research

AHAF awards 22 new grants to scientists worldwide for innovative vision research

Healthy diet might help reduce risk of macular degeneration

Anabasis, Scil Proteins enter license deal for rhNGF to treat eye diseases

STSI joins JAX consortium to develop targeted cancer therapies

Positive top line data from Mimetogen MIM-D3 Phase II clinical trial for dry eye disease

Ivantis receives $17 MM NEA, Delphi Ventures funds to expand Hydrus device clinical activities

Anticholinergic drugs might increase risk of cognitive impairment, death in older people

New VEP technique fast and effective for detecting glaucoma damage

Functional vision restored after 55 years

InNexus files patent protection for new Age-related Macular Degeneration therapeutic

Pfizer, pSivida partner to develop latanoprost implant for ocular hypertension and glaucoma

Cypress receives FDA approval for ZUTRIPRO, REZIRA NDA to treat cough and common cold

Schepens, Mass. Eye and Ear to create world's largest ophthalmology research center

Paladin to commercialize Silenor for treatment of insomnia in Canada, South America and Africa

New Westchester Montefiore Laser and Eye Center to offer ophthalmology services

Denali, Can-Fite sign agreement to conclude ophthalmology spinoff

Research: Gene mutation causes eye disease glaucoma

Wills Eye Institute and Thomas Jefferson University create new vision research center

The Incubation Factory, UMDNJ and NJIT partner to commercialize personal tonometer for glaucoma

Positive results from Astellas Pharma's mirabegron phase III trial in overactive bladder

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Glaucoma News and Research

Latest Glaucoma News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in